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INTRODUCTION 
Progressive respiratory failure associated with chronic colonization of the lung by 
Pseudomonas  aeruginosa  is the major cause of death in patients with cystic fibrosis (CF). The 
length of pulmonary colonization with P.  aeruginosa  is associated with a shortened lifespan 1. 
The production of extracellular toxins, the induction of mucin production by respiratory 
epithelial cells, and the formation of immune Complexes in the lung in response to 
Pseudomonas  8nd it's toxins all implicate the orgaQism as a pathogen in CF. 
The use of antibiotics in the treatment of CF pulmonary disease is based on several 
premises: 1) Pseudomonas  is a pathogen in the lung of CF patients, 2) eradication of 
Pseudomonas  from the respiratory tract of CF patients will stop progression of lung 
destruction and 3) eradication is an attainable goal of therapy Antibiotic therapy may have 
played 8 role in the improved survival rate of CF patients in the last 20 years, but clinical 
studies have not clearly demonstrated a positive role for antibiotics in the treatment of acute 
pulmonary exacerbations of CF. Earlier diagnosis, improved nutritional C8re and aggressive 
pulmonary physiotherapy may also have contributed to the improved survival of CF patients. 
Significant obstacles to the effective antibiotic treatment of P.  aeruginosa  pulmonary 
infections in CF persist. Despite the use of antibiotics that have in vitro activity against this 
pathogen, treatment rarely sterilizes the sputum of CF patients. Moreover, the repeated use 
of antibiotics in this patient population has been associated with the development of antibiotic 
resistance Over the course of many treatments the respiratory tract of CF patients can 
become colonized with multiple strains of resistant Pseudomonas  Thus, the search for new 
antibiotics that possess in vitro activity against this organism and that will improve clinical 
and microbiologic outcomes in these patients continues. 
investigations of the efficacy of new antibiotics in the treatment of CF pulmonary 
infections are ongoing at the University of Utah, where more than 200 CF patients receive 
medical care. Clinical trials during 1985 and 1986 centered around ciprofloxacin and 
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aztreonam. Both of these new agents have significant in vitro activity against P.  aeruginosa 
4-7 
Aztreonam is a monocyclic beta-lactam derivative. It h8s a narrow spectrum of 
action with no activity against Gram-positive organisms. The antibiotic acts by binding to 
penicillin-binding protein 3 (PBP 3) of Gram-negative organisms. Beta-lactams that bind 
exclusively to PBP 3 inhibit bacterial septation, causing filamentous growth, without rapid 
lysis. It has been suggested that this property may be a disadvantage when rapid 8nd complete 
bacterial lysis is essential, but may be advantageous when the products of bacterial lysis may 
lead to severe inflammation 8. Aztreonam is resistant to hydrolysis by most beta-lactamases 
and is a poor inducer of beta-lactamase production In addition, it may have little cross-
reactivity with other beta-lactams in beta-lactam allergic patients 1 
Ciprofloxacin is a quinolone derivative. Quinolones  have a chemical structure and 
mechanism of action vastly different from other antibiotic classes. They inhibit DNA gyrase, 
an enzyme that inserts negative supercoils into bacterial DNA. The supercoiling of bacterial 
DNA is essential to condense a large amount of genetic material into a space small enough to be 
contained in the cell. This function is required for bacterial replication. In addition, 
supercoiling is integral to bacterial gene expression. The inhibition of DNA gyrase may 
impair bacterial gene expression, including chromosomal and plasmid genes coding for 
pathogenic features 11. 
OBJECTIVES 
The foremost objective of this study was to compare the in vitro susceptibility of P. 
aeruginosa  isolates from CF patients to these new antibiotics 8nd to other currently used or 
investigational antipseudomonal agents. It is important to describe susceptibility and 
resistance patterns in a population like this in which frequent and varied antibiotic exposure 
may lead to unique resistance patterns. If a specific trend in resistance becomes apparent, 
institution-wide changes in antibiotic use can be implemented to optimize antibiotic therapy. 
Therefore, in this investigation we not only compared new agents to present therapy, but the 
results should also serve as a benchmark with which to compare future susceptibility 
patterns and direct formulary decisions. 
Ciprofloxacin and aztreonam are antibiotics with structures unique from those of 
other presently used agents. Resistance patterns between these new agents and other classes of 
antibiotics have not been described in our institution. Therefore, the incidence of concomitant 
resistance between these new agents and other antipseudomonals was also investigated. 
The rapid emergence of resistance to antibiotics during therapy has been observed 
with P.  aeruginosa  and can limit the usefulness of some antibiotics against this pathogen. To 
assess the potential for resistance developing during initial exposure to aztreonam, the 
susceptibility of clinical isolates from patients treated with aztreonam were determined 
before, during, and after therapy. 
In summary, this study had several purposes. 1) to describe the in vitro sensitivity 
of 79 isolates of P.  aeruginosa  from CF patients to ciprofloxacin, aztreonam and nine other 
antipseudomonal antibiotics, 2) to assess the incidence of concomitant resistance between 
these new antibiotics 8nd other antipseudomonal antibiotics, and 3) to assess the potential for 
rapidly developing resistance to aztreonam during initial therapy. 
METHODS 
Clinical specimens of P.  aeruginosa  were isolated from the sputum of CF patients 
enrolled in clinical trials conducted at the University of Utah Hospital during 1985 and 
1986. Patients with exacerbations of their pulmonary disease severe enough to be 
hospitalized were recruited. A total of 79 isolates were obtained before antibiotic treatment 
was begun. Fifty seven of these isolates were from 26 patients randomized to receive 
aztreonam. The remainder were from 15 patients being enrolled into ciprofloxacin trials. 
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To assess the potential development of resistance to aztreonam during therapy, only 
those clinical isolates of P.  aeruginosa  from patients with positive sputum cultures on the last 
day of therapy or on follow up were studied. Thirty eight isolates were obtained from 18 
patients before aztreonam therapy. Additionally, 22 isolates were obtained from 13 patients 
on the last day of therapy and 31 isolates from 15 patients were obtained 7 to 14 days after 
therapy with aztreonam. The length of aztreonam therapy averaged 12.5 days. 
All isolates were identified by standard microbiological methods 1 2 a n ( j stored on 
tryptic soy agar slants. The organisms were subcultured on Columbia agar to check for purity 
prior to in vitro sensitivity testing. 
Standard reference powders were supplied by the following sources: ciprofloxacin and 
azlocillin, Miles Pharmaceuticals, West Haven, CT; aztreonam, E.R. Squibb, Princeton, NJ; 
cefoperazone, Roerig, New York, NY, cefsulodin, Abbott Pharmaceuticals, North Chicago, IL; 
ceftazidime,Glaxo, Research Triangle Park, NC; ticarcillin, Beecham Laboratories, Bristol, 
TN; amikacin, Brisol Laboratories, Syracuse, NY; piperacillin, Lederle Laboratories, Wayne, 
NJ, gentamicin, Schering, Kenilworth, N«J; tobramycin, Eli Lilly, Indianapolis, IN. Stock 
solutions were prepared according to National Committee for Clinical Laboratory Standards 
(NCCLS) guidelines 13. 
The minimum inhibitory concentration (MiC) was determined by microbroth dilution. 
Mueller-Hinton broth, supplemented with cations of calcium and magnesium (final 
concentrations: 50mg/L and 25mg/L, respectively) was diluted with the appropriate 
antibiotic concentration to provide a twofold dilution from 128 mcg/mL to 0.25 mcg/mL. 
Microtiter pl8tes were stored at -20°C and used within 30 days. An actively growing 0.05mL 
inoculum of P.  aeruginosa  , adjusted to a 0.5 McFarland standard, W8S placed in each 
microtiter well and further diluted with the appropriate concentration of antibiotic to yield a 
final concentration of approximately 5 x 105 colony forming units (CFU)/mL. The MIC was 
defined as the lowest concentration of drug that yielded no visible growth after 18 hours of 
incubation at 35°C. Control organisms, Escherichiacoli  (ATCC 25922) and P.  aeruginosa 
5 
(ATCC 27853), were included in all sets of inoculations. The results were considered valid if 
the MICs of the control organisms were within one twofold dilution of established values. 
The minimum bactericidal concentration (MBC) was determined by subculturing 0.01 
mL from each microtiter well onto Mueller-Hinton agar. The MBC W8S defined as the 
concentration of drug that yielded not more than five colonies after 18 hours of incubation at 
35°C. NCCLS standard susceptibility and resistance breakpoints were used when possible 1 3 
» 
Susceptibility guidelines for ciprofloxacin, cefsulodin, and aztreonam were obtained from the 
manufacturers. 
RESULTS 
The MIC and MBC of the test antibiotics against 79 clinical isolates of P.  aeruginosa 
from cystic fibrosis patients are shown in Table 1. Ciprofloxacin was the most active 
antibiotic, with 951 of isolates inhibited by 1 mcg/mL. Of the extended-spectrum 
penicillins, azlocillin was most active, followed by piperacillin. The cephalosporins were 
comparable, with cefsulodin and ceftazidime exhibiting slightly greater activity than 
cefoperazone. The activity of aztreonam W8S similar to that of the other beta-lactam 
antibiotics. Tobramycin was the most active of the aminoglycosides. 
The incidence of concomitant resistance between test antibiotics is presented in Table 
2. Only two clinical isolates demonstrated resistance to ciprofloxacin. Both of these isolates 
were also resistant to all aminoglycosides and to aztreonam, but sensitive to the 
cephalosporins and extended-spectrum penicillins. Three clinical isolates exhibited 
resistance to all cephalosporins and extended-spectrum penicillins, demonstrating 
susceptibility only to ciprofloxacin 8nd aminoglycosides. Cephalosporin-resistant isolates 
tended to exhibit resistance to extended-spectrum penicillins. Isolates resistant to aztreonam 
(MIC>32 mcg/mL) were, in general, also resistant to cephalosporins and extended-spectrum 
penicillins. 
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The MIC50 a n d MIC90 of aztreonam and the 10 other antibiotics for P.  aeruginosa 
isolates obtained before, at the end of, and 8fter aztreonam therapy are presented in Table 3. 
MBC50 and MBC90 teta are presented in Table 4. The susceptibility of these isolates to 
aztreonam remained relatively constant with aztreonam treatment. The percent of susceptible 
isolates (MIC< 8mcg/mL) to aztreonam before, at the end of, 8nd following aztreonam 
treatment were 79, 78, and 81$, respectively. The susceptibility to the other antibiotics 
generally remained within one twofold dilution of that for the organisms isolated prior to 
exposure to aztreonam. 
DISCUSSION 
9 
The role of in vitro sensitivity tests in the evaluation of antibiotics to treat pulmonary 
exacerbations of CF is controversial. In vitro tests do not duplicate in vivo conditions. 
Moreover, it is impossible to correlate the results of in vitro sensitivity tests with clinical 
outcome because of the many other variables involved in the treatment of CF patients, such as 
chest physiotherapy and improved nutrition. On the other hand, in vitro sensitivity tests offer 
a reproducible method for comparing antibiotics in the treatment of a disease for which no 
animal model exists. 
Drusano and associates have proposed a model for comparing antibiotics that 
incorporates the pharmacokinetic properties of antibiotics and the in vitro sensitivity of the 
microbial pathogen. Specifically, the duration of free antibiotic concentration in serum 8bove 
the MIC90 for the pathogen was used to compare antibiotics. Drusano's model may have 
limited applicability in the treatment of pulmonary infections because serum concentrations 
do not accurately reflect lung antibiotic concentrations. Antibiotic characteristics, such 8s 
molecular weight, the degree of protein binding, and lipid solubility, influence penetration 
into the lungs. Host factors, such as inflammation also determine the concentration of 
antibiotics in the lung. The measurement of antibiotic concentrations at the site of infection in 
7 
CF, the bronchial mucosa, requires biopsy 8nd is therefore rarely performed. Consequently, 
sputum antibiotic concentrations are frequently used to approximate bronchial mucosa 
concentrations. Problems with sample collection, including the dilution of sputum with saliva 
and the timing of sputum collection in relation to antibiotic administration may limit the 
applicability of sputum antibiotic concentrations. 
Other factors unique to CF may limit the development of a model to compare 
antibiotics. For example, Smith and collegues 1 5 f^nd the bioactivity of aminoglycosides to be 
decreased in the presence of sputum from CF patients. Concentrations of drug 25 times higher 
than the MIC were required for a bactericidal effect in the presence of CF sputum . It h8s been 
hypothesized that aminoglycosides may be antagonized in the lungs of CF patients by the 
presence of divalent cations, exopolysaccharides, changes in pH, and binding to proteins and 
mucous 1 5 
* 
Though in vitro sensitivity tests are not directly applicable to clinical use, they 
remain a useful tool for evaluating the potential usefulness of new antibiotics in CF pulmonary 
disease. However, efforts to construct a model incorporating pharmacokinetic variables and in 
vitro susceptibility data in the evaluation of antibiotics in CF is complicated by our lack of 
knowledge about antibiotic concentrations in the lung and possible antagonism of antibiotic 
activity in the CF lung. 
In Vitro Activity of Ciprofloxacin and 10 Other Antibiotics Against 
P.  aeruginosa  from CF Patients 
This investigation clearly indicates marked in vitro activity of ciprofloxacin against 
clinical isolates of P.  aeruginosa  It should be noted, however, that these isolates were all 
obtained prior to exposure to this new agent and that these susceptibility patterns may change 
with ongoing or repeated ciprofloxacin use. Ciprofloxacin-resistant P.  aeruginosa  strains 
have developed during therapy of cystic fibrosis 8nd other infections 16-19. The mechanism 
of resistance has not been identified 2 0 but is apparently not plasmid mediated 2 1 . DNA 
gyrase activity is necessary for the transfer and expression of bacterial plasmids. Therefore, 
the action of ciprofloxacin as a DNA gyrase inhibitor may preclude the development of plasmid 
mediated resistance. 
A quinolone-resistant clinical isolate of £. coli has been characterized that 
demonstrates an alteration in a subunit of DNA gyrase 22 Alterations of DNA gyrase may not 
represent competitive survival mechanisms for bacteria, since the efficient functioning of 
this enzyme is imperative for replication and gene expression. The question of whether 
organisms which become resistant to quinolones by an alteration in DNA gyrase will retain 
their virulence properties remains unresolved. The observation that ciprofloxacin-resistant 
P.  aeruginosa  revert back to sensitive isolates after removal of the drug may indicate that 
9 
their mechanisms of resistance are not competitive with quinolone-sensitive isolates. 
•i 
An interesting observation in this study was the occurence of concomitant resistance to 
ciprofloxacin and aminoglycosides. Only two isolates had high-level resistance to all 
aminoglycosides (gentamicin and tobramycin MIC >32mcg/mL, amikacin MIC >128mcg/mL) 
and these also exhibited resistance to ciprofloxacin. Several investigators have hypothesized 
that high-level aminoglycoside resistance in P.  aeruginosa  is mediated by reduced uptake of 
the antibiotic into the cell 23-25 one could speculate that membrane impermeability was 
also responsible for ciprofloxacin resistance in these isolates. Another investigator has noted 
that the MIC50 and MIC90 of gentamicin-resistant (MIC>6mcg/mL) P.  aeruginosa  for 
ciprofloxacin was higher than that of susceptible isolates ? 
Over the course of time, cystic fibrosis patients may become colonized with multiply 
drug-resistant P.  aeruginosa  Our results indicated no concomitant resistance between beta-
lactam antibiotics and ciprofloxacin. Therefore, ciprofloxacin, an antibiotic with a structure 
and mechanism of action dissimilar to other currently available agents, could play an 
important role in the treatment of multiply drug-resistant isolates of this organism. 
These findings support the continued clinical investigation of the use of this antibiotic 
in CF. Whether ciprofloxacin, which can be administered orally, will yield equivalent or 
superior microbiologic and clinical results to standard intravenous antibiotic regimens is 
currently being investigated. Clinical trials at other CF treatment centers indicate that 
ciprofloxacin has efficacy comparable to other available antibiotics 26,27 j^e results of 
studies investigating the in vitro sensitivity of P.  aeruginosa  from CF patients at other 
treatment centers have yielded results similar to ours The use of an oral drug, such as 
* 
ciprofloxacin, in the treatment of CF patients could"have a positive impact on their quality of 
life and the cost of their care. 
Considerations other than efficacy may limit the clinical utility of ciprofloxacin. The 
use of quinolones has not been recommended in children because cartilage toxicity associated 
with naladixic acid has been observed in growing animals. Experience in adults has yielded 
some unique adverse reactions associated with quinolones that may be related to the toxicity 
seen in 8nimals. Bailey and associates described two renal transplant recipients who developed 
tendonitis associated with norfloxacin therapy 29 one of these patients had a recurrence of 
his symptoms with rechallenge. One could speculate that tendonitis may be dose-related and 
associated with norfloxacin accumulation due to decreased renal excretion. The development of 
swollen and tender metacarpal joints has also been reported 30. 
Other observations are also noteworthy. The rate of susceptibility to amikacin, an agent 
which we have seldom used in our CF population was surprisingly low (67$ sensitive, 24% 
intermediate and 9$ resistant). Susceptibility to gentamicin, despite very little use in this 
population for a number of years, was also very low. On the other hand, the rate of 
susceptibility to tobramycin, our most commonly used aminoglycoside, remains high. This 
finding is consistent with that of Gordts and collegues who found a low r8te of tobramycin-
resistant isolates from CF patients in comparison to other clinical isolates 3 1 . 
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in Vitro Activity and Lack of Development of Resistance 
During Aztreonam Therapy 
The preliminary results of clinical trials evaluation aztreonam in the treatment of 
pulmonary exacerbations of CF have demonstrated efficacy comparable to other regimens 
32,38,39 Based u p o n these findings, it appears that aztreonam holds promise for the 
treatment of P.  aeruginosa  infections in CF patients. Its narrow spectrum of action, poor 
activity as a beta-lactamase inducer, and proported low potential for cross-reactivity in the 
beta-lactam allergic patient may increase its value in the treatment of CF pulmonary 
exacerbations. 
In this investigation, the in vitro activity of aztreonam was no better than that of 
other beta-lactams. The combined use of aztreonam with other beta-lactams has been 
¥ 
advocated as an avenue of avoiding aminoglycoside toxicity and achieving synergy by targeting 
different penicillin-binding proteins 3 3 The observations that aztreonam interacts 
synergistically in vitro with amikacin and to a limited extent with other beta-lactams 
against P.  aeruginosa  may further extend its value in this setting. 
The rapid emergence of resistance during therapy can limit the clinical usefulness of 
an antibiotic. Imipenem, a new carbapenem antibiotic, has been associated with rapidly 
developing resistance in the treatment of P.  aeruginosa  pulmonary exacerbations in CF. Over 
10 days of treatment, the percentage of resistant strains increased from 9$ to 37$ 3 6 The 
mechanism of resistance has been investigated in a small number of imipenem-resistant P. 
aeruginosa  and found to be associated with a  change in outer membrane permeability The 
development of resistance during therapy C8n also occur due to beta-lactamase production. 
Aztreonam, unlike imipenem, is a poor inducer of beta-lactamase production 9. 
The apparent lack of resistance emerging during initial therapy with aztreonam is 
encouraging. Whether this finding will recur with increased use and re-exposure to 
aztreonam remains to be seen. Significant resistance emerging dur ing therapy has not been 
reported in clinical investigations of aztreonam in CF patients 32,38 
S319V1 
TABLE 1. 
ANTIBACTERIAL ACTIVITY OF TEST ANTIBIOTICS FOR 79 CLINICAL ISOLATES OF P.  AERUGINOSA  FROM CF PATIENTS 
Test Agent MIC50 MIC90 MIC Range MBC50 MBCgg MBC Range S.B. £ Isolates 
Susceptible 
Ciprofloxacin <0.125 0.5 <0.125-8 0.5 2 £0.125-32 i l 95 
Aztreonam 2 64 <0.125~> 128 8 >128 <0.125->128 <8 76 
Cefoperazone 4 64 <0.125->128 64 >128 0.5-> 1 28 <16 82 
Cefsulodin 2 32 <0.125->128 8 >128 0.25->1 28 <.16 85 
Ceftazidime 2 32 <0.125->128 4 >128 0.5->1 28 18 84 
Ticarcillin 32 >128 0.25-> 128 64 >128 0.5->1 28 x* <16 48 
Azlocillin 8 >128 0.5->128 64 >128 0.5->1 28 164 82 
Piperacillin 4 128 <0.125->128 32 >128 0.25->1 28 116 78 
Gentamicin 8 32 1-128 16 
1 A 
128 1->128 14 49 
Amikacin 16 32 0.5->128 32 128 1->128 116 67 
Tobramycin 2 8 <0.125->128 4 6 4 . <0.125->128 14 82 
All MIC, MBC and susceptibility breakpoint (S.B.*) values in units of mcg/mL. 
TABLE . 
CONOOMITANT RESISTANCE PATTERNS OF 79 CLINICAL ISOLATESOF P.  AERUGINOSA  FROM CF PATIENTS 
DRUG(N) 
GENT (23) -
TOBR (5) 4 
AMIK (7) 4 2 
TICR (13) 3 1 2 
AZLO (1 4) 5 2 4 7 
PIPR (12) 5 1 3 8 8 
\ 
AZTR (9) 4 3 3 5 5 6 
CIPR (2) 2 2 2 0 0 0 2 
CEFO (7) 3 1 2 6 7 7 5 0 
CFSU (8) 3 1 1 5 7 6 5 0 6 
CFTZ (7) 3 1 2 6 6 5 5 0 5 5 -
GENT TOBR AMIK TICR AZLO PIPR 
* 
AZTR CIPR CEFO CFSU CFTZ 
(N)=Number of resistant isolates 
Gentamicin(GENT), Tobramycin(TOBR), Amikacin(AMIK), Ticarcillin(TICR), 
Azlocillin(AZLO), Piperacillin (PIPR), Aztreonam (AZTR), Ciprofloxacin (CIPR), 
Cefoperazone (CEFO), Cefsulodin (CFSU), Ceftazidime (CFTZ). 
TABLE 3. 
INHIBITORY ACTIVITY OF TEST AGENTS BEFORE, AT THE END OF AND AFTER AZTREONAM THERAPY 
MIC50 (mog/ml) MICgo (mcg/ml) Range (mcg/ml) 
(n) 




S, <0.125 <0.125 0,5 1 0.5 <0.125-8 <0.125-8 <0,125-1 
(38) (21) (30) 
Aztreonam 2 1 2 64 64 64 <0.125->1 28 <0.1 25->128 <0.125->128 
(38) (22) (31) 
Cefoperazone 2 2 4 64 128 128 0.5-> 128 0.25->128 0.5->1 28 














16 32 64 0.5-> 128 0.25-64 0.5->128 
Ticarcillin 16 32 32 64 >128 128 0.5-> 128 0.5-> 128 iO.125->128 







128 >128 >128 0.5-> 128 0.5-> 128 0.5->128 
Piperacillin 4 4 4 128 >128 64 0.5-> 128 0.5-> 128 0.25->128 
(38) (22) (31) 
Gentamicin 4 4 4 16 64 16 1-128 <0.125-128 0.5-16 







32 64 32 0.5->128 0.5-128 1-64 
Tobramycin 1 1 2 8 8 4 <0.125-> 1 28 0.25-64 <0.125-128 
(38) (21) (30) 
TABLE . 
BACTERICIDAL ACTIVITY OF TEST AGENTS BEFORE, AT THE END OF AND AFTER AZTREONAM THERAPY 
MBC50 (mcg/ml) MBCgg (mcg/ml) Range (meg/ml) 
(n) 
Before End After Before End After Before End After 
Ciprofloxacin 0.5 0.5 0.5 1 4 1 <0.125-32 <0.125-32 <0.125-64 
(38) (21) (31) 
Aztreonam 16 2 8 >128 >128 >128 <0.125->128 <0.1 25->128 <0.125->128 
(38) (22) (31) 
Cefoperazone 64 16 32 >128 >128 >128 1->128 0.25->128 0.5-> 128 
(38) (22) (31) 
Cefsulodin 8 16 8 >128 128 >128 0.25->128 0.5-> 128 1->128 
(38) (22) (31) 
Ceftazidime 4 8 8 >128 >128 >128 0.5-> 128 0.5-> 128 0.5->128 
(38) (22) (31) 
Ticarcillin 64 64 64 >128 >128 >128 0.5-> 128 0.5-> 128 0.5->l 28 
(38) (22) (30) t 
Azlocillin 128 32 64 >128 >128 >128 1->128 0.5->128 0.5->128 
(38) (22) (31) 
Piperacillin 32 32 32 >128 >128 >128 0.5-> 128 0.5> 128 0.5-> 128 
(38) (22) (31) 
Gentamicin 16 8 16 128 128 64 1 — >128 <.0.12 5 - > 1 28 0.5-> 128 
(38) (22) (31) 
Amikacin 32 16 32 128 64 128 1->128 0.5-128 1->128 
(38) (20) (31) 
Tobramycin 2 1 2 64 32 32 0.25-> 128 0.25-H28 <0.125->128 
(38) (20) (31) 
16 
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